gene was specifically deleted in neural and glial cell precursors, has revealed potentially new roles for ATP7A in neural circuits and also will be pivotal in distinguishing and investigating the specific contributions of ATP7A and copper to neurodevelopment and neurodegeneration.
Phenotypic, biochemical, histological, and behavioral parameters were compared across the Atp7a
Nes , wild-type (WT), and mottled brindled (Atp7a Mo-br ) mice, the latter a model of Menkes disease with Atp7a mutated in all cells. Table 1 summarizes the phenotypic and neurological differences between the Atp7a
Nes and Atp7a Mo-br mice. Brain copper levels in the Atp7a
Nes mice were normal to elevated compared with WT mice, whereas copper levels in the Atp7a
Mo-br mice were approximately three-fold lower than WT, consistent with previous reports (Table 1) . Some elevation of brain copper in the Atp7a Nes mice would be expected, and perhaps it is surprising that a more significant increase in brain copper was not observed since ATP7A expression in the brain barriers [bloodbrain barrier (BBB) and blood cerebrospinal fluid barrier (BCB)] was left intact, allowing normal copper entry into the brain. In the absence of ATP7A to export their copper, astrocytes, which are known to efficiently take up and store copper, and neurons should then accumulate copper, potentially explaining the observed elevated brain copper levels.
It has been previously suggested and now supported by Hodgkinson et al. (8) that the loss of function of copperdependent enzymes alone cannot account for the severe neurodegeneration that is characteristic of Menkes patients and mouse models. The Atp7a Nes mice displayed defective copper transport into the secretory pathway but did not exhibit the typical neurodegenerative features and spontaneous seizures seen in the Atp7a
Mo-br mice (Table 1 ). These observations provide a clear demonstration that the loss of ATP7A-mediated copper delivery to cuproenzymes per se does not fully explain the neurodegeneration in Menkes disease.
Copper plays a role at the synapse and in synaptic transmission (2) and in the past decade, a physiological role for copper in regulating neuronal excitability has emerged to account for the seizures and neuronal degeneration characteristic of Menkes disease. ATP7A-dependent release of synaptic copper from rat hippocampal neurons in response to NMDA receptor stimulation was neuroprotective, and in the absence of ATP7A, hippocampal neurons from Atp7a
Mo-br mice were sensitive to glutamate-mediated NMDA receptor-dependent excitotoxicity (see references 2, 10). The protective mechanism involved endogenous nitric oxide production and S-nitrosylation of the NMDA receptor as a means of modulating its excitotoxic responsiveness. Significantly, this copper-mediated neuropro-tective S-nitrosylation of the NMDA receptor appears to also involve an association between copper and the prion protein (PrP C ), an interaction that is blocked by A␤ oligomers, inducing neurotoxicity (2) .
For the first time, the Atp7a
Nes mice allow an assessment of the specific functional contribution of ATP7A to the coppermediated neuroprotection against excitotoxic NMDA stimulation. Despite sensitivity to NMDA receptor activation, con- 
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firming a role for ATP7A in protection against NMDA receptor-mediated excitotoxicity, the absence of spontaneous seizure activity and severe neurodegeneration in the Atp7a Nes mice suggests that other mechanisms also operate to promote neuroprotective synaptic copper release. Could exosomes play a role in copper-mediated neuroprotection? Based on the association of numerous metal homeostasis proteins with exosomes, and in particular metal-binding disease-associated proteins such as PrP C and A␤, a case has been made for the role of exosomes in copper release from neurons and astrocytes (1).
Niciu et al. (9) identified neuropathology in the Atp7a
Mo-br mice among subsets of neurons (for example, Purkinje cell degeneration) that was specifically related to mutant ATP7A in a role independent of copper transport. In addition, ATP7A plays a role in axonal outgrowth and synaptogenesis, and hence synaptic plasticity, and these phenomena are disrupted in Atp7a Mo-br mice, also potentially contributing to neurodegeneration (5). The Atp7a
Nes mice now provide an opportunity to further dissect the specific role of ATP7A (or loss thereof) versus copper in cytoskeletal pathology and during development in axonal targeting and synaptogenesis.
New insights into ATP7A function within the CNS. Observations in the Atp7a
Nes mice also raised the issue of the directionality of copper flow across the brain barriers, a topic that has generated some discussion in the literature. Documented evidence supports the long-held view that copper entry into the brain is mediated by ATP7A at the basolateral membrane of BBB endothelial cells, whereas the BCB, comprising epithelial cells of the choroid plexus (CP), functions in maintaining copper homeostasis of cerebrospinal fluid (CSF). Here, ATP7A at the basolateral membrane of CP epithelial cells functions to efflux excess copper back into the circulation, and the related but kinetically slower copper-ATPase, ATP7B, is concentrated at the apical membrane to transport copper into the CSF (10) (Fig. 1) . However, based on ATP7A gene therapy at the CP (3) it was proposed that ATP7A at the apical membrane of CP cells plays a role in copper entry into the brain. Hodgkinson et al. (8) also detected increased abundance of ATP7A protein in CP epithelial cells of the Atp7a Nes mice, which, combined with the elevated hippocampal copper levels, is consistent with a role for ATP7A-mediated copper entry via the BCB and may reflect compensatory changes arising from loss of ATP7A in the CNS. Exploiting the CP tropism of adeno-associated virus serotype 5 (AAV5) used for ATP7A gene therapy (3), targeted disruption of Atp7a expression, specifically in the CP epithelia of the Atp7a Nes mice, may help to clarify its role in regulating the direction of copper transport across the BCB.
The Atp7a Nes mice have not only revealed potential new roles for ATP7A in neuronal circuits controlling normal growth and anxiety, but provide a tool to directly investigate these ATP7A functions, as well as copper handling within the amygdala, which is important for learned fear behaviors (6) . Further, since copper dysregulation is a pathological feature of several neurodegenerative and cognitive diseases (e.g., AD, PD, prion disease), crossing the Atp7a Nes mice with mouse models of these diseases will establish whether ATP7A depletion confers increased susceptibility to these diseases, hence revealing its contribution to learning and memory, and whether the CNS copper sufficiency of the Atp7a Nes mice influences the neuropathology of the disease models.
Concluding remarks. A significant outcome from the study by Hodgkinson et al. (8) was the demonstration that the severe neuropathology of Menkes disease stems from profound copper deficiency in the CNS, secondary to systemic copper deficiency, rather than from ATP7A deficiency within the CNS per se. This strengthens the argument for early copper delivery into the CNS. Lipophilic ionophoric copper compounds that can cross the brain barriers to rescue the copper deficiency would seem to hold most promise for treatment of Menkes disease. Several classes of such copper-coordinating compounds (hydroxyquinolines, dithiocarbamates, and thiosemicarbazones) are being investigated for their therapeutic potential in neurodegenerative diseases including AD, PD, and HD (4).
In summary, this contribution by Hodgkinson et al. (8) helps to clarify the role of ATP7A and copper in CNS function and integrity, and it paves the way for new discoveries relating to the specific and unique roles of ATP7A in the CNS. The challenge is to exploit this new model to reveal the full extent of ATP7A function in the CNS, as well as novel therapeutic strategies based on rescue of critical copper-mediated processes.
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